Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2017-10, Vol.179 (2), p.339-341
Hauptverfasser:	Mason, Christopher, Savona, Steven, Rini, Josephine N., Castillo, Jorge J., Xu, Lian, Hunter, Zachary R., Treon, Steven P., Allen, Steven L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - administration & dosage Antineoplastic Agents - pharmacokinetics Bing Neel syndrome Biomarkers Blood-brain barrier Blood-Brain Barrier - metabolism Brain Central Nervous System Neoplasms - diagnosis Central Nervous System Neoplasms - drug therapy Central Nervous System Neoplasms - secondary CXCR4 Hematology Humans ibrutinib Immunophenotyping Magnetic Resonance Imaging Male Middle Aged MYD88 Positron Emission Tomography Computed Tomography Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - pharmacokinetics Pyrazoles - administration & dosage Pyrazoles - pharmacokinetics Pyrimidines - administration & dosage Pyrimidines - pharmacokinetics Tomography, X-Ray Computed Treatment Outcome Waldenstrom Macroglobulinemia - complications Waldenstrom Macroglobulinemia - diagnosis Waldenstrom Macroglobulinemia - drug therapy Waldenström macroglobulinemia
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!